Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pertti J Neuvonen

Showing results (31-40 of 199) with videos related to

Pageof 20
Sort By:
European Journal of Clinical Pharmacology|June 8, 2006
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeineJanne T Backman, Marika T Granfors, Pertti J Neuvonen
European Journal of Clinical Pharmacology|October 24, 2007
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidineJanne T Backman, Marika T Schröder, Pertti J Neuvonen
Journal of Clinical Pharmacology|January 12, 2008
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideAnnikka Kalliokoski, Mikko Neuvonen, Pertti J Neuvonen, et al.
Drug Safety|September 16, 2004
Prescription of hazardous drugs during pregnancyHeli Malm, Jaana Martikainen, Timo Klaukka, et al.
Basic & Clinical Pharmacology & Toxicology|September 28, 2004
Effect of itraconazole on the pharmacokinetics of inhaled lidocaineMika H Isohanni, Pertti J Neuvonen, Klaus T Olkkola
Clinical Pharmacology and Therapeutics|March 6, 2004
Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprololJari J Lilja, Laura Juntti-Patinen, Pertti J Neuvonen
British Journal of Clinical Pharmacology|April 2, 2005
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjectsJari J Lilja, Janne T Backman, Pertti J Neuvonen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2006
Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactionsMarjo J Karjalainen, Pertti J Neuvonen, Janne T Backman
Basic & Clinical Pharmacology & Toxicology|May 17, 2006
Effect of rifampicin on the pharmacokinetics of atenololJari J Lilja, Laura Juntti-Patinen, Pertti J Neuvonen
European Journal of Clinical Pharmacology|July 10, 2007
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretationMarjo J Karjalainen, Pertti J Neuvonen, Janne T Backman
Pageof 20

Showing results (31-40 of 199) with videos related to

Sort By:
Pageof 20
European Journal of Clinical Pharmacology|June 8, 2006
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeineJanne T Backman, Marika T Granfors, Pertti J Neuvonen
European Journal of Clinical Pharmacology|October 24, 2007
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidineJanne T Backman, Marika T Schröder, Pertti J Neuvonen
Journal of Clinical Pharmacology|January 12, 2008
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideAnnikka Kalliokoski, Mikko Neuvonen, Pertti J Neuvonen, et al.
Drug Safety|September 16, 2004
Prescription of hazardous drugs during pregnancyHeli Malm, Jaana Martikainen, Timo Klaukka, et al.
Basic & Clinical Pharmacology & Toxicology|September 28, 2004
Effect of itraconazole on the pharmacokinetics of inhaled lidocaineMika H Isohanni, Pertti J Neuvonen, Klaus T Olkkola
Clinical Pharmacology and Therapeutics|March 6, 2004
Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprololJari J Lilja, Laura Juntti-Patinen, Pertti J Neuvonen
British Journal of Clinical Pharmacology|April 2, 2005
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjectsJari J Lilja, Janne T Backman, Pertti J Neuvonen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2006
Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactionsMarjo J Karjalainen, Pertti J Neuvonen, Janne T Backman
Basic & Clinical Pharmacology & Toxicology|May 17, 2006
Effect of rifampicin on the pharmacokinetics of atenololJari J Lilja, Laura Juntti-Patinen, Pertti J Neuvonen
European Journal of Clinical Pharmacology|July 10, 2007
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretationMarjo J Karjalainen, Pertti J Neuvonen, Janne T Backman
Pageof 20